Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022 DOI Creative Commons
Jubby Marcela Gálvez, Ángela María Pinzón-Rondón,

Henry Mauricio Chaparro-Solano

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(9), P. 1461 - 1461

Published: Sept. 7, 2023

Vaccination has proven to be one of the most effective strategies against COVID-19 pandemic. Several studies have evaluated and confirmed its effectiveness in different populations, particularly reducing severe outcomes such as hospitalization death. Some investigated vaccination infection, identifying need for booster doses. This study aimed explore schedule on probability infection a sample Colombian patients during fourth wave pandemic, which was associated with emergence predominance Omicron variant. A cross-sectional conducted individuals who underwent RT-PCR testing detection dedicated laboratory Bogotá, Colombia, between 30 December 2021 7 February 2022. total 1468 subjects included study, whom 36.6% (n = 538) had positive PCR test COVID-19. The comparison fully vaccinated dose those without revealed 28% reduction odds (OR 0.719 CI 0.531-0.971). Age 1.009 1.001-1.018) low economic status 1.812 1.416-2.319) were an increased risk infection. These findings suggest general population improve prevention rates SARS-CoV-2 mitigate outcomes.

Language: Английский

Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein DOI Creative Commons
Muhammad S. Khan, Eun Young Kim,

Alex McPherson

et al.

Antibody Therapeutics, Journal Year: 2022, Volume and Issue: 5(3), P. 177 - 191

Published: July 1, 2022

Additional COVID-19 vaccines that are safe and immunogenic needed for global vaccine equity. Here, we developed a recombinant type 5 adenovirus vector encoding the SARS-CoV-2 S1 subunit antigen nucleocapsid as fusion protein (Ad5.SARS-CoV-2-S1N). A single subcutaneous immunization with Ad5.SARS-CoV-2-S1N induced similar humoral response, along significantly higher S1-specific cellular alone (Ad5.SARS-CoV-2-S1). Immunogenicity was improved by homologous prime-boost vaccination, further through intramuscular heterologous vaccination using protein. Priming low dose (1 × 10

Language: Английский

Citations

11
A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection DOI Creative Commons
Santa-Mariela Olivera-Ugarte,

Marilène Bolduc,

Marie-Ève Laliberté-Gagné

et al.

Nanomedicine Nanotechnology Biology and Medicine, Journal Year: 2022, Volume and Issue: 44, P. 102584 - 102584

Published: July 16, 2022

A vaccine candidate to SARS-CoV-2 was constructed by coupling the viral receptor binding domain (RBD) surface of papaya mosaic virus (PapMV) nanoparticle (nano) generate RBD-PapMV vaccine. Immunization mice with coupled enhanced antibody titers and T-cell mediated immune response directed RBD antigen as compared immunization non-coupled formulation (RBD + PapMV nano). Anti-RBD antibodies, generated in vaccinated animals, neutralized infection vitro against ancestral, Delta Omicron variants. At last, susceptible (K18-hACE2 transgenic mice) induced protection ancestral infectious challenge. The induction broad neutralization variants demonstrate potential platform development efficient vaccines respiratory infections.

Language: Английский

Citations

11
Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies DOI Creative Commons
Ming-Chen Yang,

Chun-Chung Wang,

Wei-Chien Tang

et al.

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(3), P. e0283473 - e0283473

Published: March 24, 2023

SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With new variants continue to emerge with greater immune escaping capability, protectivity of available vaccines is compromised. Therefore, development a vaccine that capable inducing immunity against including omicron strains urgent need. In this study, we developed protein-based BCVax consisted antigen delta strain spike protein QS21-based adjuvant AB801 nanoparticle stimulation complex format (AB801-ISCOM). Results from animal studies showed high level anti-S IgG was induced after two doses neutralizing multiple pseudovirus BA.1 or BA.2 strains. addition, strong Th1 response stimulated immunization. Furthermore, BCvax AB801-ISCOM as significant stronger compared using aluminum hydroxide plus CpG 1018 adjuvant. also evaluated booster prior vaccinations, titers neutralization activities BA.4/BA.5 were further enhanced suggesting promising candidate booster. Taken together, pre-clinical data warrant for clinic.

Language: Английский

Citations

6
Practical Considerations for Next-Generation Adjuvant Development and Translation DOI Creative Commons
William R. Lykins, Christopher B. Fox

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(7), P. 1850 - 1850

Published: June 29, 2023

Over the last several years, there has been increased interest from academia and pharmaceutical/biotech industry in development of vaccine adjuvants for new emerging modalities. Despite this, adjuvant still some longest timelines pharmaceutical space, discovery to clinical approval. The reasons this are manyfold range complexities translation animal human models, concerns about safety or reactogenicity, challenges sourcing necessary raw materials at scale. In review, we will describe current state art many technologies how they should be approached applied products. We postulate that factors considered tools earlier on pipeline improve likelihood success. These recommendations may require a modified approach common practices product but would result more accessible practical adjuvant-containing

Language: Английский

Citations

5
Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022 DOI Creative Commons
Jubby Marcela Gálvez, Ángela María Pinzón-Rondón,

Henry Mauricio Chaparro-Solano

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(9), P. 1461 - 1461

Published: Sept. 7, 2023

Vaccination has proven to be one of the most effective strategies against COVID-19 pandemic. Several studies have evaluated and confirmed its effectiveness in different populations, particularly reducing severe outcomes such as hospitalization death. Some investigated vaccination infection, identifying need for booster doses. This study aimed explore schedule on probability infection a sample Colombian patients during fourth wave pandemic, which was associated with emergence predominance Omicron variant. A cross-sectional conducted individuals who underwent RT-PCR testing detection dedicated laboratory Bogotá, Colombia, between 30 December 2021 7 February 2022. total 1468 subjects included study, whom 36.6% (n = 538) had positive PCR test COVID-19. The comparison fully vaccinated dose those without revealed 28% reduction odds (OR 0.719 CI 0.531-0.971). Age 1.009 1.001-1.018) low economic status 1.812 1.416-2.319) were an increased risk infection. These findings suggest general population improve prevention rates SARS-CoV-2 mitigate outcomes.

Language: Английский

Citations

5